AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Biomerica Inc

Healthcare US BMRA


Last update at 2024-02-22T20:47:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Income before tax -7.08900M -4.50732M -6.45598M -2.33166M -2.36882M
Minority interest - - - - -
Net income -7.14000M -4.53104M -6.46904M -2.33905M -2.39306M
Selling general administrative 6.08M 5.70M 4.61M 2.27M 2.03M
Selling and marketing expenses - - - - -
Gross profit 0.45M 2.98M 0.50M 1.78M 1.29M
Reconciled depreciation 0.35M 0.59M 0.38M 0.40M 0.16M
Ebit -7.22300M -4.53396M -6.52248M -2.40285M -2.41279M
Ebitda -6.87200M -3.91250M -6.07976M -1.93302M -2.20587M
Depreciation and amortization 0.35M 0.62M 0.44M 0.47M 0.21M
Non operating income net other - - 0.07M - 0.04M
Operating income -7.22300M -4.53396M -6.52248M -2.40285M -2.41279M
Other operating expenses 12.56M 23.41M 13.72M 9.10M 7.61M
Interest expense - 0.03M 0.00037M 0.00001M 0.00005M
Tax provision 0.05M 0.02M 0.01M 0.00739M 0.02M
Interest income 0.13M 0.03M 0.07M 0.07M 0.04M
Net interest income 0.13M 0.03M 0.07M 0.07M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M 0.02M 0.01M 0.00739M 0.02M
Total revenue 5.34M 18.87M 7.20M 6.69M 5.20M
Total operating expenses 7.67M 7.51M 7.02M 4.18M 3.70M
Cost of revenue 4.89M 15.89M 6.70M 4.91M 3.91M
Total other income expense net 0.00100M 0.03M 0.07M 0.07M 0.04M
Discontinued operations - - - - -
Net income from continuing ops -7.14000M -4.53104M -6.46904M -2.33905M -2.39306M
Net income applicable to common shares -7.14000M -4.53104M -6.46904M -2.33905M -2.39306M
Preferred stock and other adjustments - - - - -
Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Total assets 14.45M 11.37M 11.82M 17.26M 5.25M
Intangible assets 0.17M 0.17M 0.29M 0.17M 0.11M
Earning assets - - - - -
Other current assets 0.30M 0.00045M 0.00026M 1.51M 0.20M
Total liab 2.73M 3.05M 2.59M 3.05M 1.26M
Total stockholder equity 11.72M 8.32M 9.23M 14.21M 3.98M
Deferred long term liab - - - - -
Other current liab 1.24M 0.88M 0.54M 0.28M 0.26M
Common stock 1.35M 1.03M 0.98M 0.94M 0.77M
Capital stock 1.35M 1.03M 0.98M 0.96M 0.77M
Retained earnings -42.21700M -35.07738M -28.39477M -21.92573M -19.58668M
Other liab - - - - -
Good will - - - - -
Other assets 0.08M 0.00036M 0.26M 0.17M 0.13M
Cash 9.72M 5.92M 4.20M 8.64M 0.69M
Cash and equivalents - - - - -
Total current liabilities 1.95M 2.01M 1.30M 1.48M 1.26M
Current deferred revenue 0.06M 0.05M - - -
Net debt -8.63700M -4.53740M -2.57980M -6.85954M -0.68678M
Short term debt 0.30M 0.34M 0.33M 0.21M -
Short long term debt - - - - -
Short long term debt total 1.08M 1.38M 1.62M 1.78M -
Other stockholder equity 52.70M 42.45M 36.69M 35.21M 22.83M
Property plant equipment 1.25M 1.52M 1.86M 1.99M 0.35M
Total current assets 12.80M 9.43M 9.23M 14.77M 4.49M
Long term investments 0.17M 0.17M 0.17M 0.17M 0.17M
Net tangible assets 11.56M 8.16M 8.93M 14.02M 3.87M
Short term investments - - - - -
Net receivables 0.72M 0.77M 1.46M 1.77M 1.45M
Long term debt - - - - -
Inventory 2.06M 2.42M 3.21M 2.85M 2.15M
Accounts payable 0.34M 0.74M 0.43M 0.99M 1.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.11000M -0.07394M -0.04796M -0.03984M -0.03653M
Additional paid in capital - - - - -
Common stock total equity - - 0.98M 0.94M 0.77M
Preferred stock total equity - - - - -
Retained earnings total equity - - -28.39477M - -19.58668M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 0.10M 0.26M 0.17M 0.13M
Deferred long term asset charges - - - - -
Non current assets total 1.66M 1.95M 2.59M 2.49M 0.75M
Capital lease obligations 1.08M 1.38M 1.62M 1.78M -
Long term debt total - - - - -
Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Investments -0.07800M -0.17034M -0.29558M -0.11893M -0.17111M
Change to liabilities -0.08000M 0.39M -0.40333M -0.01288M 0.36M
Total cashflows from investing activities -0.07800M -0.17034M -0.29558M -0.11893M -0.17111M
Net borrowings - - - - -
Total cash from financing activities 9.39M 2.39M 1.11M 12.37M 1.91M
Change to operating activities -0.20100M 0.28M 0.91M -1.49573M 0.10M
Net income -7.14000M -4.53104M -6.46904M -2.33905M -2.39306M
Change in cash 3.80M 1.72M -4.44172M 7.95M -0.51812M
Begin period cash flow 5.92M 4.20M 8.64M 0.69M 1.20M
End period cash flow 9.72M 5.92M 4.20M 8.64M 0.69M
Total cash from operating activities -5.47400M -0.48053M -5.25175M -4.29750M -2.24404M
Issuance of capital stock 10.01M 2.40M 1.01M 12.15M 1.78M
Depreciation 0.35M 0.59M 0.38M 0.40M 0.16M
Other cashflows from investing activities - - -0.15973M - -0.06997M
Dividends paid - - - - -
Change to inventory 0.53M 1.56M -1.90601M -0.71746M 0.02M
Change to account receivables -0.29100M 1.37M -0.45561M -0.30909M -0.67013M
Sale purchase of stock - - 1.11M - 1.90M
Other cashflows from financing activities -0.62400M -0.00721M 0.10M 2.14M 0.13M
Change to netincome 1.35M -0.14314M 2.69M 0.18M 0.18M
Capital expenditures 0.08M 0.17M 0.30M 0.12M 0.17M
Change receivables - - -0.45561M - -0.67013M
Cash flows other operating - - 1.28M - 0.09M
Exchange rate changes - - -0.00812M - -0.01039M
Cash and cash equivalents changes - - -4.44172M - -0.51812M
Change in working capital -0.03800M 2.91M -1.85299M -2.53729M -0.18802M
Stock based compensation 1.19M 1.26M 0.38M 0.20M 0.15M
Other non cash items 0.17M -0.71915M 2.32M -0.03797M 0.01M
Free cash flow -5.55200M -0.65087M -5.54733M -4.41643M -2.41515M


  • Previous Close 1.08
  • Market Cap20.44M
  • Volume109220
  • P/E Ratio-
  • Dividend Yield1.52%
  • EBITDA-6.01900M
  • Revenue TTM5.42M
  • Revenue Per Share TTM0.36
  • Gross Profit TTM 0.45M
  • Diluted EPS TTM-0.41

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Biomerica Inc
0.05 4.77% 1.13 0.0 0.0 4.35 2.19 3.06 -2.7471
Abbott Laboratories
1.10 0.93% 118.97 37.15 23.15 4.67 4.97 4.88 19.38
Stryker Corporation
5.88 1.69% 353.44 44.07 24.94 5.51 6.12 6.05 25.73
Medtronic PLC
-0.83 0.97% 85.07 26.60 15.87 3.35 2.08 3.90 14.12
Boston Scientific Corp
1.01 1.54% 66.76 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News


Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Biomerica Inc

17571 Von Karman Avenue, Irvine, CA, United States, 92614

Key Executives

Name Title Year Born
Mr. Zackary S. Irani Chairman & CEO 1966
Mr. Allen C. Barbieri Exec. Vice-Chairman & Corp. Sec. 1958
Mr. Steven Sloan CFO & Treasurer 1970
Ms. Lucy Liu Ph.D. Director of Manufacturing & Technical Operations NA
Hans Boehringer Sr. VP of POC R&D NA
Mr. Robert W. Carlson Chief Commercial Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).